Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Marinus Pharmaceuticals
Biotech
Marinus lays off 20% to steady ship after IV seizure med issues
Marinus is implementing a raft of cost-cutting measures in the wake of last month's phase 3 fail—including waving goodbye to a fifth of its workforce.
James Waldron
May 8, 2024 9:42am
Marinus sells priority review voucher to Novo Nordisk for $110M
Jul 14, 2022 10:50am
Stability woes torpedo Marinus' phase 3 seizure timeline
Feb 23, 2022 7:15am
Marinus tees up phase 3 for rare epilepsy med
Aug 18, 2021 11:16am
Marinus signs $30M upfront deal with Orion for antiseizure med
Aug 3, 2021 3:55pm
Sinking Marinus gets a lifeline with new ganaxolone data
Jan 23, 2017 7:51am